Skip to main content
Premium Trial:

Request an Annual Quote

Pfizer Licenses Valentis GeneSwitch System

NEW YORK, Oct. 25 – Pfizer licensed Valentis’ GeneSwitch gene regulation technology, the companies announced on Wednesday.

The license is non-exclusive for research-use only.

Financial details of the agreement were not disclosed.

Burlingame, Calif.-based Valentis’ GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, according to the company.

In August, Lexicon Genetics licensed Valentis’ GeneSwitch system for use in its functional genomics research.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.